

1 **The safety and efficacy of mesenchymal stem cells in the treatment of COVID-19-associated pneumonia:**  
2 **a systematic review and meta-analysis**

3 Wang Junwu<sup>a,1</sup>, Shi Pengzhi<sup>b,1</sup>, Chen Dong<sup>a</sup>, Wang Shuguang<sup>b</sup>, Wang Pingchuan<sup>a</sup>, Feng Xinmin<sup>a</sup>,  
4 Zhang Liang<sup>a,2</sup>

5 <sup>1</sup> Co-first authors.

6 **Affiliations:**

7 <sup>a</sup> Department of Orthopedics, Clinical Medical College of Yangzhou University, Yangzhou 225001,  
8 China

9 <sup>b</sup> Graduate School of Dalian Medical University, Dalian 116000, China

10 **The full contact details of corresponding author Liang Zhang are list below:**

11 <sup>2</sup>: Liang Zhang; PhD; Clinical Medical College of Yangzhou University, No.98 Nantong West Road,  
12 Yangzhou, 225001, Jiangsu province, China; Tel: 0086-18952578137; E-mail:  
13 zhangliang6320@sina.com

14 **Abstract**

15 Mesenchymal stem cells (MSCs) therapy is considered one of the most promising treatments in the  
16 context of the coronavirus disease 2019 (COVID-19) pandemic. However, the safety and  
17 effectiveness of MSCs in the treatment of COVID-19-associated pneumonia patients need to be  
18 systematically reviewed and analyzed. Two independent researchers searched for the relevant studies  
19 published between October 2019 and April 2021 in PubMed, Embase, Cochrane Library, WAN  
20 FANG, and CNKI databases. A total of 22 studies involving 371 patients were included in the  
21 present study. MSCs were administered in 247 participants, and MSCs were allogeneic from  
22 umbilical cord, adipose tissue, menstrual blood, placenta, Wharton's jelly, or unreported sources.  
23 Combined results found that MSCs group significantly reduced the incidence of adverse events (OR  
24 = 0.43, 95%CI. = 0.22~0.84, P = 0.01) and mortality (OR = 0.17, 95%CI. = 0.06~0.49, P < 0.01),  
25 and the difference compared with control group was statistically significant. No MSCs treat-related  
26 serious adverse events were reported. The lung function and radiographic outcomes, and biomarker  
27 levels of inflammation and immunity all showed improvement trends. Therefore, MSCs therapy is an  
28 effective and safe method in the treatment of COVID-19-associated pneumonia and shows advantages  
29 in less adverse events and mortality. However, a standard and effective MSCs treatment program  
30 needs to be developed.

31 **Keywords:** COVID-19, SARS-CoV-2, Mesenchymal stem cells, Mortality, Systematic review

32 **Declarations**

33 **Funding**

34 This study was supported by Jiangsu Provincial Medical Youth Talent [grant number  
35 QNRC2016342]; Project on Maternal and Child Health Talents of Jiangsu Province [grant number  
36 F201801]; and Six Talent Peaks Project in Jiangsu Province [grant number LGY2019035]. No  
37 benefits in any form have been or will be received from a commercial party related directly or  
38 indirectly to the subject of this manuscript.

39 **Authors' contributions**

40 **Wang Junwu:** Material preparation, Data collection and analysis, Methodology, Formal analysis,  
41 investigation, and Writing - original draft. **Shi Pengzhi:** Conceptualization, Material preparation,  
42 Data collection and analysis, Methodology, Formal analysis and investigation. **Chen Dong:** Material  
43 preparation, Data collection and analysis, Methodology, Formal analysis and investigation. **Wang**  
44 **Shuguang:** Material preparation, Data collection and analysis, Methodology, Formal analysis and  
45 investigation. **Wang Pingchuan:** Material preparation, Data collection and analysis, Formal analysis  
46 and investigation. **Feng Xinmin:** Conceptualization, Methodology, Writing - review and editing,  
47 Supervision, Resources. **Zhang Liang:** Conceptualization, Methodology, Writing - review and  
48 editing, Funding acquisition, Resources, Supervision. All authors contributed to the study conception  
49 and design.

50 **Availability of data and materials**

51 All data generated or analyzed during this study are included in this published article and its supplementary  
52 information files.

53 **Ethics approval and consent to participate**

54 Not applicable.

55 **The safety and efficacy of mesenchymal stem cells in the treatment of COVID-19-associated pneumonia:**  
56 **a systematic review and meta-analysis**

57 **Abstract**

58 Mesenchymal stem cells (MSCs) therapy is considered one of the most promising treatments in the  
59 context of the coronavirus disease 2019 (COVID-19) pandemic. However, the safety and  
60 effectiveness of MSCs in the treatment of COVID-19-associated pneumonia patients need to be  
61 systematically reviewed and analyzed. Two independent researchers searched for the relevant studies  
62 published between October 2019 and April 2021 in PubMed, Embase, Cochrane Library, WAN  
63 FANG, and CNKI databases. A total of 22 studies involving 371 patients were included in the  
64 present study. MSCs were administered in 247 participants, and MSCs were allogeneic from  
65 umbilical cord, adipose tissue, menstrual blood, placenta, Wharton's jelly, or unreported sources.  
66 Combined results found that MSCs group significantly reduced the incidence of adverse events (OR  
67 = 0.43, 95%CI. = 0.22~0.84, P = 0.01) and mortality (OR = 0.17, 95%CI. = 0.06~0.49, P < 0.01),  
68 and the difference compared with control group was statistically significant. No MSCs treat-related  
69 serious adverse events were reported. The lung function and radiographic outcomes, and biomarker  
70 levels of inflammation and immunity all showed improvement trends. Therefore, MSCs therapy is an  
71 effective and safe method in the treatment of COVID-19-associated pneumonia and shows advantages  
72 in less adverse events and mortality. However, a standard and effective MSCs treatment program  
73 needs to be developed.

74 **Keywords:** COVID-19, SARS-CoV-2, Mesenchymal stem cells, Mortality, Systematic review

75 **1 Introduction**

76 Coronavirus disease 2019 (COVID-19), an infectious disease caused by a novel severe acute  
77 respiratory syndrome coronavirus 2 (SARS-CoV-2), has been sweeping the globe. According to data  
78 reported by the World Health Organization, as of 13 June 2021, 175 333 154 confirmed cases of

79 COVID-19 have been documented in global countries, areas, or territories with 3 793 230 deaths,  
80 and 2 655 782 new cases and 72 528 new deaths were reported in the past week [1]. COVID-19 has  
81 been associated with an intensive care unit (ICU) admission rate of 5% of proven infections [2] and a  
82 high mortality rate of critically ill patients [3]. This series of cruel numbers has prompted an urgent  
83 need for treatments that can solve serious cases and prevent fatal consequences [4].

84 Based on preclinical and clinical studies, mesenchymal stromal cells (MSCs) are found can regulate  
85 inflammation and remodeling processes, and restore the concept of alveolar-capillary dysfunction,  
86 and thus MSC is considered as a potential treatment for COVID-19 [5,6]. MSCs are pluripotent cells  
87 and can be obtained from a variety of tissues, preferably including bone marrow, adipose tissue,  
88 placenta, umbilical cord, and dental pulp [7-12]. It is noteworthy that a controlled study by Leng [13]  
89 showed that seven patients in MSCs treatment group were cured or the symptoms were significantly  
90 improved after 14 days of angiotensin-converting enzyme 2 (ACE2) negative MSCs injection, and  
91 inflammation and immune function levels were also ameliorated without observed adverse effects.  
92 The outcomes of three patients in control group found one death, one acute respiratory distress  
93 syndrome (ARDS), and one remained severely condition. Therefore, they believed that intravenous  
94 transplantation of MSCs was safe and effective for the treatment of patients with COVID-19  
95 pneumonia, especially for the critically severe patients. Fortunately, the application of MSCs in the  
96 treatment of COVID-19 has been well studied not only in terms of symptomatic efficacy, but also in  
97 inflammation, immunity, and molecular mechanisms since then [14,15].

98 Therefore, this article conducted a systematic review and meta-analysis of the currently available  
99 literature on MSCs treatment of COVID-19 since COVID-19 was first reported in 2019, to analyze  
100 its safety and efficacy and investigate the potential value of MSCs therapy in patients with COVID-  
101 19 infection.

## 102 **2 Methods**

## 103 **2.1 Literature Search**

104 The systematic review was performed according to Preferred Reporting Items for Systematic  
105 Reviews and Meta-Analyses guidelines [16]. Literature was searched with no language restrictions  
106 by two independent researchers. Since COVID-19 was first reported in Wuhan China and  
107 subsequently confirmed [17,18], we searched for articles published between October 2019 and April  
108 2021 in PubMed, Embase, Cochrane Library, WAN FANG, and CNKI databases. The terms used for  
109 the search were as follows: “novel coronavirus” OR “2019 coronavirus disease” OR  
110 “novel coronavirus disease 2019” OR “2019-nCoV” OR “COVID-19” OR “SARS CoV-2” OR  
111 “severe acute respiratory syndrome-coronavirus-2” and “stem cell”. Articles from the same authors  
112 or institutions were examined, and duplicate data sets were excluded. The number of articles  
113 included and excluded was shown in a flow chart (**Fig. 1**).

## 114 **2.2 Eligibility Criteria**

115 We included randomized controlled trials (RCT), clinically controlled studies (CCT), retrospective  
116 studies, case reports, letters (with valid data), and case series that evaluated the safety and/or efficacy  
117 of MSCs administered to adult patients with a diagnosis of COVID-19 pneumonia from any cause.  
118 MSCs that were culture-expanded or minimally manipulated were included. Studies were excluded if  
119 they did not report original data (eg, reviews, editorials, letters, commentary, opinion, guidelines, or  
120 erratum).

## 121 **2.3 Data Extraction**

122 The extracted data were as follows. Data from articles were extracted independently by two  
123 reviewers and verified by the third reviewer if there was a disagreement.

### 124 **2.3.1 General data**

125 The general data were shown in **Table 1-3** (Author name, publication year, country, study design,

126 number of cases, age, gender, and follow-up were shown in **Table 1**; baseline disease severity,  
127 comorbidities, general condition, and imaging outcomes were shown in **Table 2**; the MSCs source,  
128 surface markers, MSCs dose per time, frequency, cells viability, and transplantation route were  
129 shown in **Table 3**). Following established clinical guidelines for the diagnosis and treatment of  
130 COVID-19, the disease severity is classified as mild, common, severe, or critical [19,20].

### 131 **2.3.2 Outcomes**

132 The primary outcome was safety based on the number of patients with adverse events (AEs),  
133 frequency of AEs, serious AEs (SAEs), and if they were related to the treatment with MSCs. Clinical  
134 outcomes included the following: general clinical symptoms (such as fever, cough, dyspnea,  
135 respiratory rate, etc), blood oxygen index (arterial blood partial pressure of oxygen (PaO<sub>2</sub>), fraction  
136 of inspiration O<sub>2</sub> (FiO<sub>2</sub>), PaO<sub>2</sub>/FiO<sub>2</sub>, arterial blood or peripheral oxygen saturation (SaO<sub>2</sub> or SpO<sub>2</sub>),  
137 etc), six- or seven- category scale, the time from intervention to recovery, and mortality.  
138 Radiographic outcomes: analysis of the lung CT scans or chest X-ray imaging. Laboratory outcomes  
139 included the time for nucleic acid turned to be negative, immune cells (dendritic cell (DC),  
140 lymphocyte (LYM), natural killer cell (NK cell), T cell, B cell, neutrophil (NE), and white blood cell  
141 (WBC)), and inflammatory cytokines (ALT, ammonia, AST, bilirubin, blood creatinine, B-type  
142 natriuretic peptide (BNP), blood urea nitrogen (BUN), creatine kinase (CK), CK-MB, C-reactive  
143 protein (CRP), cardiac troponin T (cTnT), D-dimer, ferritin, fibrinogen, granulocyte-macrophage  
144 colony-stimulating factor (GM-CSF), interferon- $\gamma$  (INF-  $\gamma$  or IFN- $\gamma$ ), IFN-g, interleukin-1RA (IL-  
145 1RA), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-18, IL-22, interferon-inducible protein-10 (IP-10),  
146 lactate (LAC); lactate dehydrogenase (LDH), monocyte chemotactic protein-1(MCP-1), macrophage  
147 inflammatory protein-1 $\alpha$  (MIP-1 $\alpha$ ), myoglobin, procalcitonin (PCT), platelet derived growth factor-  
148 BB (PDGF-BB), regulated upon activation normal T cell expressed and secreted factor (RANTES),  
149 tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), TNF- $\beta$ , triglyceride, and vascular endothelial growth factor  
150 (VEGF)).

## 151 **2.4 Quality Assessment**

152 The methodological quality of each study included in the present meta-analysis was evaluated by the  
153 National Heart Lung and Blood Institute (NHLBI) quality assessment tools (**Table S1**) [21]. All  
154 studies were classified as either good, fair, or poor.

## 155 **2.5 Statistical Analysis**

156 Data are presented as n (%) for categorical variables and mean  $\pm$  standard deviation for continuous  
157 variables. Mortality and the number of patients with AEs were the only two outcomes deemed to be  
158 appropriate for meta-analysis. The Review Manager v.5.3 software was used to merge in each study  
159 and an overall estimate of the effect was shown in the form of forest plot. We used  $I^2$  indicator to  
160 evaluate heterogeneity between studies. Sensitivity analysis by eliminating one of all included  
161 studies at a time and subgroup analysis was performed to examine the source of the heterogeneity  
162 when heterogeneity existed ( $I^2 > 50\%$ ). The random-effects model was used if heterogeneity still  
163 existed. Otherwise, the fixed-effects model was used ( $I^2 < 50\%$ ). The final selected model was used  
164 to summarize the odds ratio (OR) of the included studies. We were unable to evaluate publication  
165 bias due to the small number of available studies.

## 166 **3 Results**

167 The literature search identified 1582 unique citations. Abstract and full-text screening identified 22  
168 studies with 371 patients to be included for the data extraction. All included studies were assessed as  
169 good [10,12,22-26,32,35,36,38,39] or fair [13,27-31,33,34,37,40] according to the NHLBI quality  
170 assessment tool (**Table S2**).

### 171 **3.1 Study characteristics**

172 Of the 22 studies [10,12,13,22-40,], there were four CCTs, three RCTs, four case series, three Letters,  
173 and eight case reports. Seven were comparative studies with control groups. All 22 studies reported

174 mortality and laboratory outcomes (n = 371); 17 studies reported AEs and SAEs (n = 273); 20  
175 studies reported general clinical symptoms and imaging outcomes after MSCs treatment (n = 324). A  
176 total of 247 patients received MSCs therapy, while 124 participated as controls (**Table 1**).

### 177 **3.2 Patient characteristics**

178 The 22 studies were from seven countries and regions, including China (n = 14) [12,13,22-25,29-31,  
179 35,36,38-40], the United States (n = 1) [26], Germany (n = 1) [27], Spain (n = 2) [28,37], Iran (n = 1)  
180 [10], Mexico (n = 1) [32], and Turkey (n = 2) [33,34]. Eleven studies reported on baseline  
181 oxygenation indicators of patients [10,13,26,27,29,30,32,35,37,38,40]. General symptoms such as  
182 fever, cough, and dyspnea were reported in 16 studies [10,12,13,23,24,27,29,32-40], and lung  
183 imaging evaluation showed COVID-19 related pneumonia in 15 studies [10,12,23,25,27,29,32-40].  
184 The disease severity of the patient's condition was Critical (n = 63), Severe (n = 260), and Moderate  
185 (n = 10) in 19 studies [10,12,13,22-25,27-34,36,38-40]; and the patients in one study were divided  
186 into "Mild-to-moderate" (n = 6) and "Moderate-to-severe" (n = 18) according to the severity of  
187 ARDS [26]. The average age of study participants was 45.1 to 61.0 years for MSCs group and 39.0  
188 to 65.0 years for control group in the comparative studies[13,22-27]. In the comparative studies, the  
189 disease severity of MSCs group were Critical (n = 13), Severe (n = 115), and Moderate (n = 8), and  
190 those of control group were Critical (n = 11), Severe (n = 105), and Moderate (n = 8) [13,22-27].  
191 The most common comorbidities including hypertension (HT, n = 105), diabetes mellitus (DM, n =  
192 61), obesity(n = 19), chronic obstructive pulmonary disease (COPD, n = 11), and heart disease (HD,  
193 n = 9) had been reported in 18 studies [10,12,13,22,23,25-30,32-35,38-40]. There were also  
194 differences in the follow-up time after MSCs treatment in these studies, ranging from a week to two  
195 months, which mainly due to the point when patients were recovery or died and discharge from the  
196 hospital (**Table 1-2**).

### 197 **3.3 Intervention method**



198 Culture-expanded allogeneic MSCs were used in all 22 included studies. Allogeneic umbilical cord-  
199 derived MSCs were used in 13 studies [22-26,29,30,32,34,36-39], Wharton's jelly-derived MSCs in  
200 three studies [12,33,40], menstrual blood- or adipose tissue- or placenta- derived MSCs were  
201 separately used in one study [10,28,35]. Four studies did not report the tissue origin of the MSCs  
202 [13,27,31,37](**Table 3**). Characterization was reported in most studies, with significant differences in  
203 details. Characterization of MSCs was reported in 11 studies, with most of the following markers:  
204 positive for CD9, CD29, CD44, CD73, CD90, CD105, HLA-ABC, and negative for CD11b, CD14,  
205 CD19, CD31, CD34, CD45, CD79 $\alpha$ , CD133 and HLA-DR [10,12,13,22-26,32,35,39]. Viability was  
206 reported to be >80% [10,12,24-27,32,35,36,39].

207 MSCs were mainly injected intravenously (n = 245), and two other patients were injected  
208 intratracheally and intravenously [33,34]. MSCs infusion frequency ranged from a single  
209 administration to five administrations (n = 47, 43, 154, 2, 1). Dosing of MSCs ranged from 1 to 2  
210 million cells per kilogram of body weight or a uniform dose of 30 to 200 million cells. Only one  
211 study did not report the dose [33].

## 212 **3.4 Safety**

### 213 **3.4.1 Adverse events**

214 We extracted data from 16 studies on the number of AEs and the number of patients with AEs to  
215 describe the occurrence of AEs (**Table 4**) [10,12,13,22,24-26,28,31-34,36-39]. In MSCs group,  
216 patients with AEs accounted for 48.33% (87/180), and the total number of AEs was 167.  
217 Additionally, according to research by Feng et al, hypoalbuminemia, insomnia, gastrointestinal  
218 diseases, and paroxysmal arrhythmia occurred in the surviving patients [30]. It is worth noting that  
219 15 treatment-related AEs were reported in five studies. Meng et al reported that two patients  
220 receiving MSCs developed transient facial flushing and fever immediately on infusion, which  
221 resolved spontaneously within 4 h; another moderate patient had a transient fever within 2 h that  
222 resolved within 24 h [22]. Chen et al reported that three cases experienced treatment-related AEs,

223 specifically liver dysfunction, heart failure and allergic rash [31]. Hashemian et al reported that two  
224 cases developed shivering that occurred during the initial MSCs infusion, which was relieved by  
225 supportive treatment in less than 1 h [10]. Iglesias et al reported that a patient had muscle  
226 contractions in extremities, and another patient had muscle contractions in extremities and chest, PO<sub>2</sub>  
227 decreased 78%, arterial hypertension, and respiratory effort; the third patient developed hypotension  
228 [32]. In the study of Lanzoni et al, a treatment-related AE was reported without specific description  
229 [26]. Comparisons of AEs incidence between MSCs group and control group were made in five  
230 studies (n = 196) [13,22,24-26,]. The overall AEs incidences were 58.0% (69/119) for MSCs-treated  
231 patients and 77.9% (60 of 77) for controls, and the difference was statistically significant (P =  
232 0.01,OR = 0.43, 95%CI. = 0.22~0.84) (**Fig. 2**).

### 233 **3.4.2 Serious adverse events**

234 In our data extraction process, the number of deaths was included in the number of SAEs if the study  
235 did not describe SAEs in detail and only reported the mortality. The results showed that 32 SAEs  
236 occurred in the 219 MSCs-treated patients in 19 studies (**Table 4**) [10,12,13,22-30,32-34,36-39].  
237 There were no reported MSCs treatment-related SAEs. The 10 SAEs reported in Xu's study included  
238 severe liver dysfunction (n = 1), expiratory dyspnea (n = 1), respiratory failure (n = 1), ARDS (n = 1),  
239 shock (n = 3), multifunctional organ failure (n = 2), and gastrointestinal bleeding (n = 1) [24]. Shi et  
240 al reported 1 case of pneumothorax in MSCs group, and the patient recovered naturally after  
241 conservative treatment [25]. Lanzoni et al reported 4 SAEs without detailed introduction [26].  
242 Häberle et al reported a death case due to multiple organ failure [27]. Sanchez-Guijo et al reported  
243 that two patients died, one from massive gastrointestinal bleeding and another one from secondary  
244 fungal pneumonia by *Saccharomyces* spp [28]. Guo et al reported 4 patients died without detailed  
245 introduction [29]. There were two SAEs during the trial reported by Feng et al [30]. The two patients  
246 suffered from bacterial pneumonia and septic shock and died of multiple organ failure or circulation  
247 and respiratory failure, respectively. Hashemian et al reported deaths of 4 patients due to multiple

248 organ failure and 1 patient due to cardiac arrest [10]. Iglesias et al reported that a case developed to  
249 left lower extremity arterial thrombosis, deterioration of hemodynamics, D-dimer concentration of  
250 7268 ng/mL and death; *Enterobacter cloacae* were cultured in aspirated samples from his trachea.  
251 The other patient developed hemodynamic alterations, epistaxis, hematuria, and died 13 days after  
252 MSCs infusion [32]. In the case report of Yilmaz, a patient was diagnosed with upper gastrointestinal  
253 bleeding, but his vital signs were stable after effective treatment [33]. Among the seven controlled  
254 studies, 136 patients in MSC groups had 16 SAEs, while 124 patients in control group had 49 SAEs  
255 [13,22-27].

## 256 **3.5 Efficacy**

### 257 **3.5.1 Mortality**

258 Mortality was reported in all included studies (**Table 4**), and the overall mortality rate was 12.94%  
259 (48/371). The mortality rate among MSCs-treated patients was 8.50% (21/247). Comparisons  
260 between MSCs group and control group were made in seven studies (n = 260), and there was a trend  
261 toward a decreased mortality rate in MSCs group in all seven studies [13,22-27]. The overall  
262 mortality rate was 3.68% (5/137) for MSCs-treated patients and 21.77% (27/124) for controls. There  
263 was a favorable trend and the difference was statistically significant ( $P < 0.01$ , OR = 0.17, 95%CI =  
264 0.06~0.49). However, the certainty of the evidence on the impact on mortality was limited due to the  
265 differences in the baseline conditions of the included patients, and the imprecision and  
266 methodological limitations of the included trials (**Fig. 3, Table 1-2**).

### 267 **3.5.2 Changes in general clinical symptoms and lung function**

268 The results found that the average time from receiving the first injection to recovery or discharge  
269 from hospital ranged from about 2 to 24 days for MSCs-treated patients (**Table 5**) [10,12,13,22-  
270 24,26,28,32, 36-40]. In several controlled studies, Shu et al, Xu et al and Lanzoni et al reported that  
271 the average time taken to improve (or recovery) for MSCs group was shorter than that of control

272 group, and the difference was statistically significant [23,24,26]. However, Meng et al reported that  
273 the duration from admission to discharge between the two groups was close [22]; and Xu et al  
274 reported that there was no significant difference in either the length of hospital stay or the number of  
275 days in the ICU between the two groups [24].

276 Changes in general clinical symptoms and pulmonary function (including oxygenation index and  
277 chest radiology examinations) after treatment were recorded in 21 studies (**Table 5**) [10,12,13,22-  
278 25,27-40]. Different studies had different assessment indicators for lung function, which made it  
279 more difficult to extract the outcomes. The general clinical symptoms and pulmonary function (such  
280 as SaO<sub>2</sub>, PaO<sub>2</sub>/FiO<sub>2</sub>, the oxygenation index, and chest CT or X-ray) were found to improve in the  
281 early days after MSCs treatment in most of the studies. Some studies reported that the clinical  
282 improvement of MSCs group showed a significant improvement than control group, and the  
283 oxygenation index of the MSCs group recovered to the normal range faster than control group  
284 [23,25,27], and CT scores, the number of lobes involved, ground-glass opacity, and consolidation,  
285 which reflected reduced lung inflammation of MSCs group, were significantly better than those of  
286 control group [22-25]. However, there was a study reported that the cough of MSCs group showed a  
287 significant improvement compared with control group at Day 1 after MSCs treatment but no  
288 difference was found at other time points; the expiratory dyspnea showed a significant improvement  
289 compared with control group at Day 1, 3, and 5, but no difference was found at Day 7, 14, and 30  
290 [25]. There was also a study reported that the saturation of pulse oxygen significantly improved in  
291 survivors compared to non-survivors even if all patients received MSCs treatment [10].

### 292 **3.4.3 Laboratory outcomes**

293 The laboratory outcomes were shown in **Table 6**. The negative status of HCoV-19 nucleic acid was  
294 evaluated in 11 studies [12,13,22,24,26,29,35-39]. The average time from receiving the first injection  
295 to the nucleic acid turned to be negative ranged from about 4 to 15.8 days for MSCs-treated patients.  
296 Comparisons between MSCs group and control group were made in two studies, and there was no

297 significant difference between the two groups [24,26].  
298 The immune cells were tested in 15 studies [12,13,23,25,27-30,32,33,35,36,38-40]. The increased of  
299 DC, LYM, NK cells, T cells and B cells, and the decrease of NE and WBC were found in most of the  
300 studies. While Guo et al reported that there was no significant difference in WBC before and after  
301 MSCs treatment [29], and Iglesias et al reported that only one patient (1/5) had a decrease in total  
302 LYM from 1570/ml to 984/ml at 7 days post-infusion[32]. In controlled studies, a significant  
303 reduction in WBC and NE, and a significant increase in LYM were be found in MSCs group  
304 compared with control group [23,27]. However, there was a study reported that there was no  
305 significant difference in the subsets of peripheral LYM counts (CD4+ T cells, CD8+ T cells, B cells,  
306 NK cells) between the two groups at Day 0, 6, 10, and 14 after the first MSCs injection [25].  
307 The inflammatory cytokines were evaluated in all studies. Most of the studies found that serum  
308 cytokines, chemokines, and growth factors improve to varying degrees following MSCs therapy.  
309 Two controlled studies reported that the concentrations of CRP, GM-CSF, IFN-g, IL-5, IL-6, IL-7,  
310 TNF- $\alpha$ , TNF- $\beta$ , PDGF-BB and RANTES in MSCs group were significantly lower than those in  
311 control group [23,26]. However, we also noticed that there was no significant difference in plasma  
312 markers (IL-6, IL-8, IFN- $\gamma$ , IL-1Ra, IL-18, MCP-1, MIP-1 $\alpha$ , and IP-10) between the two groups  
313 reported in two controlled studies [25,27].

#### 314 **4. Discussion**

315 It is exciting that some specific vaccines against the SARS-CoV-2 virus have been produced and  
316 promoted to vaccinate. In mainland China, people are being vaccinated for free in a planned way,  
317 and a total of 1 095.902 million doses of SARS-CoV-2 vaccines have been vaccinated as of June 23,  
318 2021 [41]. However, the shortage of vaccines vaccine-related AEs and virus variant strains have kept  
319 some countries and regions in the shadow of the raging COVID-19 epidemic [42-46]. On this basis,  
320 other active treatments are still essential. At present, a considerable number of studies have analyzed

321 the possibility of MSCs in the treatment of COVID-19, and some clinical trial results have confirmed  
322 its effectiveness. Therefore, this meta-analysis inspected the published results of MSCs treatment of  
323 COVID-19 patients, with focused analysis on safety, efficacy, and related pulmonary responses and  
324 immunologic. Our analysis of the studies found that MSCs therapy is safe and shows the potential to  
325 extenuate the damage of immunity and inflammation to the lungs and other organs and decrease the  
326 mortality of COVID-19 patients.

#### 327 **4.1 Safety**

328 Safety is the primary concern for any new therapies, especially in patients at high risk of death due to  
329 treatment, and was carefully assessed for MSCs-treated patients in the reviewed studies. This study  
330 analyzed the occurrence of AEs and found that MSCs group had fewer patients with AEs than  
331 control group in five controlled studies [13,22,24-26], and the difference was statistically significant.  
332 Fifteen transient AEs related to MSCs treatment were reported [10,22,26,31,32], but most of them  
333 resolved spontaneously in a short time. Regrettably, 32 SAEs occurred in the 219 MSCs-treated  
334 patients, but the authors of these studies believed that none of these SAEs were found to be related to  
335 MSCs therapy [10,12,13,22-30,32-34,36-39]. Additionally, the number of SAEs of MSCs group was  
336 also less than that of control group in the controlled studies [13,22-27]. The safety is consistent with  
337 the experience of other human clinical trials involving MSCs treatment [47,48].

338 The mortality of patients infected with COVID-19 was used as the primary outcome to analyze the  
339 potential efficacy of MSCs therapy in this study. All seven controlled studies reported that MSCs  
340 group is associated with reduced mortality [13,22-27], and the pooled estimates of mortality showed  
341 that the mortality rate of MSCs group is significantly lower than that of control group (3.68% vs.  
342 21.77%). The difference suggests that MSCs treatment may be effective in reducing mortality of  
343 these patients.

344 The COVID-19 disease accompanied with notable hematological manifestations, thrombocytopenia,  
345 and coagulation abnormalities on presentation and associated with poor outcomes during the disease

346 courses [49]. There was a study reported that despite low molecular weight heparin prophylaxis or  
347 full anticoagulant therapy, the incidence of deep vein thrombosis, mainly asymptomatic, in  
348 hospitalized COVID-19 patients was 14.5% [50]. However, some patients had to suspend  
349 anticoagulation therapy due to bleeding or anemia and eventually died of hemodynamic disorders  
350 [32]. It is worth mentioning that 10 patients were already in very serious condition before receiving  
351 MSCs treatment and died of multiple organ failure or hemodynamic disorders [10,27,30,32,37].  
352 Although their condition improved within a few days after MSCs transplantation, this sympathetic  
353 treatment failed to save their lives. Therefore, the authors of present study considered that although  
354 MSCs treatment could play a positive role in most COVID-19 patients and help save their lives,  
355 there are still individual differences in its efficacy.

#### 356 **4.2 Efficacy**

357 The results of three studies showed that the average time of improvement (or recovery) in MSCs  
358 group was significantly shorter than that of control group [23,24,26], while two studies showed that  
359 the length of hospital stay was not different between the two groups [22,24]. The authors of present  
360 study believed that the reason for this difference was that the time from the onset of symptoms to the  
361 diagnosis of SARS-CoV-2 or hospitalization of patients was different in these studies. Therefore, it is  
362 not believed that the difference in the length of hospital stay is statistically significant in these studies  
363 with a small number of included cases and no uniform admission criteria.

364 Hashemian et al reported that non-survivors did not get the same amelioration in saturation of pulse  
365 oxygen as survivors even though all patients received MSCs treatment [10]. A case report showed  
366 that the patient's consciousness and mental state began to improve after MSCs treatment, and his  
367 pulmonary compliance increased significantly, but extracorporeal membrane oxygenation (ECMO)  
368 and mechanical ventilation could not be resolved due to no significant improvement in lung function  
369 and chest CT scans. The treatment results were not satisfactory even after receiving five times MSCs  
370 injections, the patient was lucky enough to receive lung transplantation but unfortunately died of



371 transplant rejection [40]. However, the general clinical symptoms, pulmonary function and  
372 radiographic imaging were found to ameliorate at the early days after MSCs treatment in most of the  
373 included studies, and the improvement in MSCs group was significantly better than that of control  
374 group. It has been found that intravenously infused MSCs migrate directly to the lung, where they  
375 can secrete a variety of factors, which play an important role in immune regulation, protection of  
376 alveolar epithelial cells, resistance to pulmonary fibrosis, and amelioration of lung function. It shows  
377 great benefits for the treatment of severe lung diseases in COVID-19 [51,52]. The findings of this  
378 study also further support the consideration of using MSCs to treat COVID-19-related pulmonary  
379 function decline.

380 The occurrence and development of SARS-CoV-2 depend on the interaction between virus infection  
381 and the immune system. Dysregulation of immune system in COVID-19 patients can contribute to  
382 serious illness. Dysregulation of the immune system such as lymphopenia and cytokine storm could  
383 be a crucial factor related to the severity of COVID-19 [49,53]. Compared with moderate COVID-19  
384 cases, severe cases more frequently had dyspnea, lymphopenia, and hypoalbuminemia, with higher  
385 levels of ALT, LDH, CRP, ferritin, and D-dimer as well as markedly higher levels of IL-2R, IL-6,  
386 IL-10, and TNF- $\alpha$ . Absolute numbers of T cells, CD4<sup>+</sup> T cells, and CD8<sup>+</sup> T cells decreased in nearly  
387 all the patients and were markedly lower in severe cases than moderate cases [20]. In severe cases,  
388 patients suffer from ARDS, which is usually associated with elevated levels of inflammatory  
389 cytokines. Therefore, rebalancing the high inflammatory response of the host immune system and the  
390 regeneration of damaged cells seems to be the main way to treat this disease [54]. The main  
391 mechanism of MSCs therapeutic effect is due to the secretion of soluble factors, such as cytokines,  
392 chemokines, angiogenic factors, growth factors, and exosomes and extracellular vesicles. It is these  
393 complex mechanisms making MSCs suitable for treating complex and multifactorial diseases for  
394 which no other reductionistic drug treatments are available yet, such as COVID-19-related ARDS  
395 and other similar inflammatory diseases that involve a cytokine storm [14,55,56]. The present study



396 found that MSCs therapy has a positive impact on the immune and inflammatory processes that lead  
397 to organ damage in COVID-19 patients. Most of the included studies showed that the number of  
398 immune cells ameliorated and serum cytoinflammatory factors gradually abated with MSCs  
399 treatment. Additionally, the WBC of patients had been corrected to the normal range before  
400 receiving MSCs injection, so there was no statistical difference before and after MSCs treatment in  
401 Guo's study [29].

#### 402 **4.3 Other findings**

403 ACE2 is the main host cell receptor for SARS-CoV-2 entry, and the virus uses the host cell  
404 transmembrane serine protease II (TMPRSS2) for Spike envelope protein priming [57]. It is known  
405 that ACE2 and TMPRSS2 are present on the surface of a variety of human cells, such as alveolar  
406 cells and capillary endothelium, while immune cells, such as T cells and B cells, and macrophage are  
407 negative for ACE2 [58]. There were studies reported that human MSCs do express neither ACE2 nor  
408 TMPRSS2, and human MSCs derived from fetal and adult tissues are not permissive to SARS-CoV-  
409 2 infection [13,59].

410 We also find out about comorbidities that the three most common comorbidities are hypertension,  
411 diabetes mellitus and obesity, which are the same as the concerns of many previous authors [60-63].  
412 As the course of diabetes mellitus prolongs and some elderly hypertension patients need to be treated  
413 with ACE inhibitors which may increase the expression of ACE2. In addition, it has been found that  
414 pioglitazone and liraglutide, which are used to control blood glucose level and up-regulate the  
415 expression of ACE2 in experimental models [64-66]. Previous studies also confirmed that  
416 comorbidities such as hypertension, diabetes, and obesity are risk factors for severe symptoms and  
417 increased mortality in COVID-19 patients [60-64,67].

#### 418 **4.4 Research significance**

419 This comprehensive systematic review and meta-analysis of published reports of MSCs therapy for

420 COVID-19 have yielded several important findings. Primarily, the number of patients with AEs in  
421 MSCs group was significantly less than that in control group, and the mortality rate was also  
422 significantly slashed (3.68% vs. 21.77%). Only 36 SAEs occurred in 219 patients treated with MSCs,  
423 and none of them was related to MSCs transplantation. Additionally, MSCs therapy plays an active  
424 role in restoring lung function and improving symptoms. Furthermore, MSCs therapy is beneficial in  
425 coping with cytokine storms and correcting immune disorders. This study provides a sympathetic  
426 treatment option for doctors and patients in areas still under the shadow of the COVID-19 outbreak  
427 and accumulates experience for coping with new challenges in the future.

#### 428 **4.5 Limitations**

429 Towards the end of this project, there are still not many clinical reports on MSCs for the treatment of  
430 COVID-19. Therefore, the limitations of this systematic review include the lack of large-scale RCTs,  
431 and no canonical treatment program and evaluation standard for MSCs. There are differences in the  
432 source, dose, activity, frequency, and inoculation interval of the MSCs in the included studies. It is  
433 unknown whether these will affect the treatment effect. Moreover, there may exist selection bias and  
434 insufficient description of the evaluation in published results.

#### 435 **5 Conclusion**

436 This systematic review and meta-analysis of existing studies demonstrated the safety and  
437 effectiveness of MSCs in the treatment of COVID-19. There is an urgent need for adequately  
438 powered clinical trials to test the clinical results of MSCs therapy on patients with COVID-19  
439 syndrome and SARS-CoV-2 infection, and to explore a standard MSCs therapy program.

#### 440 **References**

- 441 1. Organization WH: Weekly epidemiological update on COVID-19 - 15 June 2021.  
442 <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---15-june-2021>.

- 443 Accessed June 20, 2021.
- 444 2. Murthy S, Gomersall C, Fowler R. Care for critically ill patients with COVID-19. *JAMA*.  
445 2020;323:1499-500.
- 446 3. Bhatraju P, Ghassemieh B, Nichols M, et al. Covid-19 in critically ill patients in the Seattle  
447 Region - Case Series. *N Engl J Med*. 2020;382:2012-22.
- 448 4. Zumla A, Hui D, Azhar E, et al. Reducing mortality from 2019-nCoV: host-directed therapies  
449 should be an option. *Lancet*. 2020;395:e35-e36.
- 450 5. Khoury M, Ikonomou L, Dominici M, et al. The coronavirus pandemic: A pitfall or a fast track for  
451 validating cell therapy products? *Stem Cells Dev*. 2021;30:119-27.
- 452 6. Esquivel D, Mishra R, Soni P, et al. Stem cells therapy as a possible therapeutic option in treating  
453 COVID-19 patients. *Stem Cell Rev Rep*. 2021;17:144-52.
- 454 7. Sengupta V, Sengupta S, Lazo A, et al. Exosomes derived from bone marrow mesenchymal stem  
455 cells as treatment for severe COVID-19. *Stem Cells Dev*. 2020;29:747-54.
- 456 8. Chen J, Hu C, Chen L, et al. Clinical study of mesenchymal stem cell treatment for acute  
457 respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: A hint for  
458 COVID-19 treatment. *Engineering*. 2020;6:1153-61.
- 459 9. Gentile P, Sterodimas A, Pizzicannella J, Calabrese C, Garcovich S. Research progress on  
460 mesenchymal stem cells (MSCs), adipose-derived mesenchymal stem cells (AD-MSCs), drugs, and  
461 vaccines in inhibiting COVID-19 disease. *Aging Dis*. 2020;11:1191-201.
- 462 10. Hashemian S, Aliannejad R, Zarrabi M, et al. Mesenchymal stem cells derived from perinatal  
463 tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. *Stem Cell Res*  
464 *Ther*. 2021;12:91.
- 465 11. Croci S, Bonacini M, Dolci G, et al. Human dental pulp stem cells modulate cytokine production  
466 in vitro by peripheral blood mononuclear cells from coronavirus disease 2019 patients. *Front Cell*  
467 *Dev Biol*. 2020;8:609204.

- 468 12. Zhang Y, Ding J, Ren S, et al. Intravenous infusion of human umbilical cord Wharton's jelly-  
469 derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia.  
470 *Stem Cell Res Ther.* 2020;11:207.
- 471 13. Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2 mesenchymal stem cells improves the  
472 outcome of patients with COVID-19 pneumonia. *Aging Dis.* 2020;11:216-28.
- 473 14. Jeyaraman M, John A, Koshy S, et al. Fostering mesenchymal stem cell therapy to halt cytokine  
474 storm in COVID-19. *Biochim Biophys Acta Mol Basis Dis.* 2021;1867:166014.
- 475 15. Desterke C, Griscelli F, Imeri J, et al. Molecular investigation of adequate sources of  
476 mesenchymal stem cells for cell therapy of COVID-19-associated organ failure. *Stem Cells Transl  
477 Med.* 2021;10:568-71.
- 478 16. Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews  
479 and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.  
480 *BMJ.* 2009;339:b2700.
- 481 17. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China,  
482 2019. *N Engl J Med.* 2020;382:727-33.
- 483 18. WJ Tan, X Zhao, XJ Ma, et al. A novel coronavirus genome identified in a cluster of pneumonia  
484 cases — Wuhan, China 2019–2020. *China CDC Weekly.* 2020;2:61-2.
- 485 19. Verity R, Okell L, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a  
486 model-based analysis. *Lancet Infect Dis.* 2020;20:669-77.
- 487 20. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate  
488 coronavirus disease 2019. *J Clin Invest.* 2020;130:2620-9.
- 489 21. Institute TNHLaB: Quality assessment tool for case series studies.  
490 <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>. Accessed April 28, 2021.
- 491 22. Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal stem cell therapy in  
492 patients with COVID-19: a phase 1 clinical trial. *Signal Transduct Target Ther.* 2020;5:172.

- 493 23. Shu L, Niu C, Li R, et al. Treatment of severe COVID-19 with human umbilical cord  
494 mesenchymal stem cells. *Stem Cell Res Ther.* 2020;11:361.
- 495 24. Xu X, Jiang W, Chen L, et al. Evaluation of the safety and efficacy of using human menstrual  
496 blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An  
497 exploratory clinical trial. *Clin Transl Med.* 2021;11:e297.
- 498 25. Shi L, Huang H, Lu X, et al. Effect of human umbilical cord-derived mesenchymal stem cells on  
499 lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2  
500 trial. *Signal Transduct Target Ther.* 2021;6:58.
- 501 26. Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19  
502 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. *Stem  
503 Cells Transl Med.* 2021;10:660-73.
- 504 27. Häberle H, Magunia H, Lang P, et al. Mesenchymal stem cell therapy for severe COVID-19  
505 ARDS. *J Intensive Care Med.* 2021;36:681-8.
- 506 28. Sánchez-Guijo F, García-Arranz M, López-Parra M, et al. Adipose-derived mesenchymal stromal  
507 cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical  
508 ventilation. A proof of concept study. *EClinicalMedicine.* 2020;25:100454.
- 509 29. Guo Z, Chen Y, Luo X, et al. Administration of umbilical cord mesenchymal stem cells in  
510 patients with severe COVID-19 pneumonia. *Crit Care.* 2020;24:420.
- 511 30. Feng Y, Huang J, Wu J, et al. Safety and feasibility of umbilical cord mesenchymal stem cells in  
512 patients with COVID-19 pneumonia: A pilot study. *Cell Prolif.* 2020;53:e12947.
- 513 31. Chen X, Shan Y, Wen Y, et al. Mesenchymal stem cell therapy in severe COVID-19: A  
514 retrospective study of short-term treatment efficacy and side effects. *J Infect.* 2020;81:647-79.
- 515 32. Iglesias M, Butrón P, Torre-Villalvazo I, et al. Mesenchymal stem cells for the compassionate  
516 treatment of severe acute respiratory distress syndrome due to COVID 19. *Aging Dis.* 2021;12:360-  
517 70.

- 518 33. Yilmaz R, Adas G, Cukurova Z, et al. Mesenchymal stem cells treatment in COVID-19 patient  
519 with multi-organ involvement. *Bratisl Lek Listy*. 2020;121:847-52.
- 520 34. Zengin R, Beyaz O, Koc E, et al. Mesenchymal stem cell treatment in a critically ill COVID-19  
521 patient: a case report. *Stem Cell Investig*. 2020;7:17.
- 522 35. Tang L, Jiang Y, Zhu M, et al. Clinical study using mesenchymal stem cells for the treatment of  
523 patients with severe COVID-19. *Front Med*. 2020;14:664-73.
- 524 36. Peng H, Gong T, Huang X, et al. A synergistic role of convalescent plasma and mesenchymal  
525 stem cells in the treatment of severely ill COVID-19 patients: a clinical case report. *Stem Cell Res*  
526 *Ther*. 2020;11:291.
- 527 37. Soler RR, Rius TJ, Melgosa CM. [Expanded mesenchymal stem cells: a novel therapeutic  
528 approach of SARS-CoV-2 pneumonia (COVID-19). Concepts regarding a first case in Spain]. *Med*  
529 *Clin (Barc)*. 2020;155:318-9.
- 530 38. Zhu Y, Zhu R, Liu K, et al. Human umbilical cord mesenchymal stem cells for adjuvant  
531 treatment of a critically ill COVID-19 Patient: A case report. *Infect Drug Resist*. 2020;13:3295-300.
- 532 39. Liang B, Chen J, Li T, et al. Clinical remission of a critically ill COVID-19 patient treated by  
533 human umbilical cord mesenchymal stem cells: A case report. *Medicine (Baltimore)*.  
534 2020;99:e21429.
- 535 40. Tao J, Nie Y, Wu H, et al. Umbilical cord blood-derived mesenchymal stem cells in treating a  
536 critically ill COVID-19 patient. *J Infect Dev Ctries*. 2020;14:1138-45.
- 537 41. China NHCotPsRo: New coronavirus vaccination status.  
538 <http://www.nhc.gov.cn/xcs/yqfkd/202106/d38cff6ee53248ae93ae4f1b808357d6.shtml>. Accessed  
539 June 23, 2021.
- 540 42. Loyo E, González M, Esparza J. Venezuela is collapsing without COVID-19 vaccines. *Lancet*.  
541 2021;397:1806.
- 542 43. Kluge H, McKee M. COVID-19 vaccines for the European region: an unprecedented challenge.

- 543 Lancet. 2021;397:1689-91.
- 544 44. Jawad N, Taweeleh L, Elharake J, et al. Refugee access to COVID-19 vaccines in Lebanon.  
545 Lancet. 2021;397:1884.
- 546 45. Blumenthal K, Robinson L, Camargo C, et al. Acute allergic reactions to mRNA COVID-19  
547 Vaccines. JAMA. 2021;325:1562-5.
- 548 46. Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on  
549 symptomatic COVID-19 infection in adults: A randomized clinical trial. JAMA. 2021: e218565.
- 550 47. Chen W, Liu W, Bai Y, et al. Transplantation of mesenchymal stem cells for spinal cord injury: a  
551 systematic review and network meta-analysis. J Transl Med. 2021;19:178.
- 552 48. Glassberg M, Minkiewicz J, Toonkel R, Simonet E, Rubio G, DiFede D, et al. Allogeneic human  
553 mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery  
554 (AETHER): A phase I safety clinical trial. Chest. 2017;151:971-81.
- 555 49. Cheung C, Law M, Lui G, et al. Coronavirus disease 2019 (COVID-19): A haematologist's  
556 perspective. Acta Haematol. 2021;144:10-23.
- 557 50. Baccellieri D, Bertoglio L, Apruzzi L, et al. Incidence of deep venous thrombosis in COVID-19  
558 hospitalized patients during the first peak of the Italian outbreak. Phlebology. 2021;36:375-83.
- 559 51. Mahendiratta S, Bansal S, Sarma P, et al. Stem cell therapy in COVID-19: Pooled evidence from  
560 SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review. Biomed Pharmacother.  
561 2021;137:111300.
- 562 52. Li Z, Niu S, Guo B, et al. Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis. Cell  
563 Prolif. 2020;53:e12939.
- 564 53. Tavasolian F, Hatam G, Mosawi S, et al. The immune response and effectiveness of COVID-19  
565 therapies. Adv Exp Med Biol. 2021;1321:115-26.
- 566 54. Afarid M, Sanie-Jahromi F. Mesenchymal stem cells and COVID-19: Cure, prevention, and  
567 vaccination. Stem Cells Int. 2021;2021:6666370.

- 568 55. Mansourabadi A, Sadeghalvad M, Mohammadi-Motlagh H, Rezaei N. The immune system as a  
569 target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-  
570 19. *Life Sci.* 2020;258:118185.
- 571 56. Yadav P, Vats R, Bano A, Bhardwaj R. Mesenchymal stem cell immunomodulation and  
572 regeneration therapeutics as an ameliorative approach for COVID-19 pandemics. *Life Sci.*  
573 2020;263:118588.
- 574 57. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2  
575 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell.* 2020;181:271-80.e278.
- 576 58. Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal  
577 epithelial cells together with innate immune genes. *Nat Med.* 2020;26:681-7.
- 578 59. Avanzini M, Mura M, Percivalle E, et al. Human mesenchymal stromal cells do not express  
579 ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection. *Stem Cells Transl Med.*  
580 2021;10:636-42.
- 581 60. Peña J, Rascón-Pacheco R, Ascencio-Montiel I, et al. (2021) Hypertension, diabetes and obesity,  
582 major risk factors for death in patients with COVID-19 in Mexico. *Arch Med Res.* 52:443-9.
- 583 61. Dennis J, Mateen B, Sonabend R, et al. Type 2 diabetes and COVID-19-related mortality in the  
584 critical care setting: A national cohort study in England, March-July 2020. *Diabetes Care.*  
585 2021;44:50-7.
- 586 62. Abu-Farha M, Al-Mulla F, Thanaraj T, et al. Impact of diabetes in patients diagnosed with  
587 COVID-19. *Front Immunol.* 2020;11:576818.
- 588 63. Tartof S, Qian L, Hong V, et al. Obesity and mortality among patients diagnosed with COVID-  
589 19: Results from an integrated health care organization. *Ann Intern Med.* 2020;173:773-81.
- 590 64. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at  
591 increased risk for COVID-19 infection? *Lancet Respir Med.* 2020;8:e21.
- 592 65. Romaní-Pérez M, Outeiriño-Iglesias V, Moya C, et al. Activation of the GLP-1 receptor by



593 liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the  
594 production of SP-A and SP-B in the lungs of type 1 diabetes rats. *Endocrinology*. 2015;156:3559-69.  
595 66. Saha S, Chakrabarti S, Singh P, et al. Physiological relevance of angiotensin converting enzyme  
596 2 as a metabolic linker and therapeutic implication of mesenchymal stem cells in COVID-19 and  
597 hypertension. *Stem Cell Rev Rep*. 2021;17:132-43.  
598 67. Singh A, Gillies C, Singh R, et al. Prevalence of co-morbidities and their association with  
599 mortality in patients with COVID-19: A systematic review and meta-analysis. *Diabetes Obes Metab*.  
600 2020;22:1915-24.

601

**Table 1** Study and patient characteristics

<b>Authors &amp; year &amp; Country</b>	<b>Study design</b>	<b>Total, n MSC; Ctrl</b>	<b>Mean age(year) MSC; Ctrl</b>	<b>Gender, n, (Male/Female) MSC ; Ctrl</b>	<b>Follow-Up</b>
Leng et al. 2020 China [13]	Phase 1, CCT	10(7; 3)	57.0; 65.0	4/3; 0/3	14 days
Meng et al. 2020 China [22]	Phase 1, CCT	18(9; 9)	45.1; 49.6	7/2; 4/5	28 days
Shu et al. 2020 China [23]	RCT	41(12; 29)	61.0; 57.9	8/4; 16/13	28 days
Xu et al. 2021 China [24]	Phase 1, CCT	44(26; 18)	58.3; 61.1	17/9; 13/5	30 days
Shi et al. 2021 China [25]	Phase 2, RCT	100(65; 35)	60.7; 59.9	37/28; 19/16	28 days
Lanzoni et al. 2021 United States [26]	Phase 1/2a, RCT	24(12; 12)	58.6; 58.8	5/7; 8/4	31 days
Häberle et al. 2021 Germany [27]	CCT	23(5; 18)	59; 39	3/2; 13/5	NR
Sánchez-Guijo et al. 2020 Spain [28]	Case series	13	60.3	1/12	28 days
Guo et al. 2020 China [29]	Research Letter	31	70 (median)	25/6	NR
Feng et al. 2020 China [30]	Case series	16	61.8	12/4	28 days
Chen et al. 2020 China [31]	Retrospective study, Letter	25	70 (median)	20/5	NR
Hashemian et al. 2021 Iran [10]	Case series	11	53.8	8/3	60 days
Iglesias et al. 2021 Mexico [32]	Case series	5	52.6	4/1	21 days
Yilmaz et al. 2020 Turkey [33]	Case report	1	51	1/0	14 days
Zengin et al. 2020 Turkey [34]	Case report	1	72	1/0	60 days
Tang et al. 2020 China [35]	Case report	2	Case 1: 37 Case 2: 71	1/1	14 days
Zhang et al. 2020 China [12]	Case report	1	54	1/0	7 days
Peng et al. 2020 China[36]	Case report	1	66	0/1	11 days
Soler et al. 2020 Spain [37]	Letter	1	NR	NR	7 days
Zhu et al. 2020 China [38]	Case report	1	48	1/0	14 days
Liang et al. 2020 China [39]	Case report	1	65	0/1	18 days
Tao et al. 2020 China [40]	Case report	1	72	1/0	41 days

602

Abbreviations: CCT: clinical controlled trial, **Ctrl**: control group, **MSC**: mesenchymal stem cell treatment group, RCT:

603

randomized controlled trial, NR: not reported

604

**Table 2** Baseline general, imaging outcomes and disease severity

Authors	Baseline general, n	Imaging outcomes	Comorbidities, n MSC; Ctrl	Disease severity, n MSC; Ctrl
Leng et al.	MSC; Ctrl: Fever: 7; 2   Cough, weak, poor appetite: 7; 3   Shortness of breath: 7; 3   SaO <sub>2</sub> : 92%; 92%	NR	HT: 1; NR	Severe: 4; 0   Critical: 3; 3
Meng et al.	NR	NR	HT: 1; 1   DM: 1; 0   FLD: 1; 0   Asthma: 0; 1	Moderate: 5; 5   Severe: 4; 4
Shu et al.	MSC; Ctrl: Fever: 10; 26   Cough: 8; 19   Respiratory rate > 24/min: 11; 20	MSC; Ctrl (Chest CT): Number of lobes involved: 4 (4, 5); 4 (3.5, 5)   GGO: 12 (100%); 29 (100%)   Linear opacities: 10 (83.33%); 26 (89.66%)   Consolidation: 11 (91.67%); 25 (86.21%)   Interlobular septal thickening: 10 (83.33%); 25 (86.21%)   Crazy-paving pattern: 7 (58.33%); 15 (51.72%)   Subpleural curvilinear line: 6 (50.00%); 10 (34.48%)   Bronchial wall thickening: 8 (66.67%); 19 (65.52%)   Lymph node enlargement: 5 (41.67%); 15 (51.72%)   Pleural effusion: 2 (16.67%); 3 (10.34%)	HT: 3; 6   DM: 3; 5	Severe: 12; 29
Xu et al.	MSC; Ctrl: Fever: 13; 8   Cough: 16; 10   Expiratory dyspnea: 8; 8   Sore throat: 2; 2   Chest tightness: 6; 9	NR	NR	Severe: 16; 10   Critical: 10; 8
Shi et al.	NR	MSC; Ctrl (Chest CT): Lesion proportion (%): total lesion volume (in cm <sup>3</sup> )/whole lung volume (in cm <sup>3</sup> ): 26.31 (11.62, 38.42); 27.98 (11.57, 44.14)   Solid component lesion proportion (%): Solid component lesion volume (in cm <sup>3</sup> )/whole lung volume (in cm <sup>3</sup> ): 2.59 (0.69, 5.20); 2.52 (0.77, 4.91)	HT: 17; 10   DM: 12; 5   CB: 2; 3   COPD: 2; 0	Severe: 65; 35
Lanzoni et al.	MSC; Ctrl: PaO <sub>2</sub> /FiO <sub>2</sub> ratio (mmHg): 126.75; 117.75	NR	HT: 7; 9   DM: 5; 6   Obesity: 11; 5	ARDS severity: Mild-to-moderate: 3; 3 Moderate-to-

Häberle et al.	All patients have severe dyspnea. <b>MSC; Ctrl:</b> ECMO: 4/5; 9/18   Temperature, °C: 37 (IQR 36.6-38.2); 39 (IQR 38-39.4)  PaO <sub>2</sub> /FiO <sub>2</sub> ratio (mmHg): 68 (IQR 58-84); 87 (IQR 68-92)	<b>MSC; Ctrl:</b> Murray lung injury score: 2.8 (IQR 2.0-3.6); 3.5 (IQR 3.3-4)	Cancer: 0; 1   HD: 1; 3 HT: 1; 13   HD: 0; 5   CAF: 0; 2   COPD: 0; 1   Asthma: 0; 1   DM: 0; 2   Smoker: 0; 3	severe: 9; 9 Severe: 5; 18
Sánchez-Guijo et al.	NR	NR	HT: 7   DM: 1   COPD: 2   Hypothyroidism: 1   HBV: 1   Smoker: 5	Critical: 13
Guo et al.	<b>MSC:</b> Fever: 24 (77.4%), cough: 25 (80.6%), dyspnea: 17 (54.8%), chest congestion: 14 (45.2%), fatigue: 12 (38.7%) PaO <sub>2</sub> /FiO <sub>2</sub> , (mmHg): 242 (200-294) <b>MSC:</b> The oxygenation index in severe patients (n = 8) and critically severe patients (n = 7) was 285.50 (197.50-469.00) mmHg and 177.14 (92.50-316.00) mmHg, respectively with the mean oxygenation index in total 258.80 (92.50-469.00) mmHg	<b>MSC (Chest CT):</b> Bilateral pneumonia: 31 (100%), multiple mottling/GGO: 26 (83.9%)	HT: 13   COPD: 6   CAD: 5   DM: 5	Severe/Critical: 23/8
Feng et al.	NR	NR	HT: 8   DM: 6   CKD: 3   HBV: 1   BA: 1   AD: 1   Anaemia: 1	Severe/Critical: 9/7
Chen et al.	NR	NR	NR	Severe: 25
Hashemian et al.	<b>MSC:</b> Fever: 10 (91%), cough: 10 (91%), dyspnea: 10 (91%), respiratory rate (> 30): 11 (100%). PaO <sub>2</sub> /FiO <sub>2</sub> ratio (IQR) 79.39% (35%)	NR <b>MSC (Chest CT):</b> Lung involvement, which included variable degrees of mixed GGO, crazy paving pattern, or consolidations with peripheral subpleural dominancy, in addition to vascular dilation, traction bronchiectasis, and pleural effusion in some cases	HT: 3   DM: 4   CMP: 1   CLL: 1	Critical: 11
Iglesias et al.	<b>MSC:</b> All patients showed varying degrees of fever, cough, dyspnea, shortness of breath, rapid heartbeat, and PaO <sub>2</sub> /FiO <sub>2</sub> decreased to an average of about 73 mmHg	<b>MSC:</b> Chest CT of five patients all showed severe pneumonia	DM: 2   HT: 1   PAD: 1   Morbid obesity: 3   Hypothyroidism: 1   Dyslipidemia: 1   Pulmonary fibrosis: 1	Critical: 5
Yilmaz et al.	<b>MSC:</b> Cough, myalgia, high fever (39.5 °C), and diarrhea. The patient developed severe bilateral pneumonia, ARDS, and multiple organ failure	<b>MSC (Chest CT):</b> The upper and lower lobes of both lungs were commonly held. The lesions seen in both lungs had GGO, and areas of consolidation were	No	Critical

Zengin et al.	<b>MSC:</b> Fever, tonsillitis, aphthous stomatitis, shortness of breath	compatible with COVID-19 infection <b>MSC</b> (chest X-ray): Atelectatic areas in the middle and lower parts of the lungs, in addition to the earlier image of GGO and patchy infiltration	HT, DM and hyperlipidemia	Critical
Tang et al.	<b>MSC:</b> Case 1: Fever. SaO <sub>2</sub> : 92%; PaO <sub>2</sub> : 66 mmHg, FiO <sub>2</sub> : 100% Case 2: Dyspnea, cough, and shortness of breath. SaO <sub>2</sub> : 98%, PaO <sub>2</sub> : 99 mmHg, and FiO <sub>2</sub> : 80%	<b>MSC:</b> Case 1: The chest X-ray indicated large, patchy, and high-density lesions in the bilateral lungs, and the costal diaphragm angle was not clear Case 2: The chest X-ray indicated patchy and high-density shadows in the lower lung fields and the left middle lung	Case 1: HT Case 2: NR	NR
Zhang et al.	<b>MSC:</b> High fever, weakness, shortness of breath, and low oxygen saturation	<b>MSC:</b> CT clearly showed evidence of pneumonia and GGO in bilateral lungs	DM	Critical
Peng et al.	<b>MSC:</b> On the fourth Day after convalescent plasma treatment (Treatment before MSC injection), the absorption of pulmonary exudative lesions was not obvious, the symptoms of dyspnea have not been significantly improved, and high-flow nasal cannula oxygen therapy were still required	<b>MSC:</b> Comparison of the two chest CT scans before MSC treatment, the pulmonary exudative lesions have no significant improvement	NR	Severe
Zhu et al.	<b>MSC:</b> Fever, cough, sputum, dyspnea, poor appetite, poor mental state, and fatigue SaO <sub>2</sub> : 75–80%	<b>MSC:</b> CT images showed GGO in both lungs	NR	Critical
Soler et al.	<b>MSC:</b> General malaise, fever and weakness, cough attack, and anorexia, dyspnea SaO <sub>2</sub> : 92%	<b>MSC:</b> CT showed a new ground-glass peripheral bronchopulmonary image at the bottom of the left upper lobe, and the persistent presence of thickened surrounding tissues of the right lung parenchyma and blood vessels	No	NR
Liang et al.	<b>MSC:</b> Severe pneumonia (mixed type), ARDS, multiorgan injury (liver, respiratory system, and blood), moderate anemia, electrolyte disturbance, immunosuppression, acute gastrointestinal bleeding, and other symptoms	<b>MSC:</b> X-ray examination showed GGO in right lung	DM, HT	Critical
Tao et al.	<b>MSC:</b> Fever, chest tightness, asthma PaO <sub>2</sub> 48.0 mmHg, PaCO <sub>2</sub> 51.0 mmHg, PaO <sub>2</sub> /FiO <sub>2</sub> 69 mmHg	<b>MSC:</b> Chest CT showed pneumonia-like properties and enlarged lesions with patchy consolidation on both sides of lung	DM, HT	Critical

606 asthma, CAD: coronary artery disease, CAF: chronic atrial fibrillation, CB: chronic bronchitis, CKD: chronic kidney  
607 failure, CLL: chronic lymphocytic leukemia, CMP: cardiomyopathy, COPD: chronic obstructive pulmonary disease, **Ctrl**:  
608 control group, DM: diabetes mellitus, ECMO: extracorporeal membrane oxygenation, FLD: fatty liver disease, GGO:  
609 ground-glass opacity, HBV: hepatitis B virus, HD: heart disease, HT: hypertension, IQR: intensive care unit, **MSC**:  
610 mesenchymal stem cell treatment group, NR: not reported, PAD: peripheral artery disease, PaCO<sub>2</sub>: arterial blood partial  
611 pressure of CO<sub>2</sub>, PaO<sub>2</sub>/FiO<sub>2</sub>: arterial blood partial pressure of oxygen (PaO<sub>2</sub>)/fraction of inspiration O<sub>2</sub> (FiO<sub>2</sub>), SaO<sub>2</sub>:  
612 oxygen saturation

613

**Table 3** Characteristics of MSCs and intervention methods

Authors	MSC source	Surface marker	MSC dose per time	Viability, %	Frequency, n(%)	Transplantation route
Leng et al.	NR	Negative: CD19, CD34, CD14, CD45, HLA-DR Positive: CD73, CD105, CD90	1 x 10 <sup>6</sup> cells/kg	NR	Once 7(100%)	IV
Meng et al.	UC	Negative: CD19, CD34, CD11b, CD45, HLA-DR Positive: CD73, CD105, CD90	3 x 10 <sup>7</sup> cells	NR	Three times 9(100%)	IV
Shu et al.	UC	Negative: CD34, CD45, CD14, CD11b, CD79α, CD19, HLA-DR Positive: CD73, CD105, CD90	2 x 10 <sup>6</sup> cells/kg	NR	Once 12(100%)	IV
Xu et al.	UC	Negative: CD117, CD34, CD45, HLA- DR Positive: CD29, CD73, CD105, CD90	3 x 10 <sup>7</sup> cells	>90	Three times 26(100%)	IV
Shi et al.	UC	Negative: CD19, CD34, CD11b, CD45, HLA-DR Positive: CD73, CD105, CD90	4 x 10 <sup>7</sup> cells	88.4	Three times 65(100%)	IV
Lanzoni et al.	UC	CD90/CD105 > 95%, CD34/CD45 < 5%	98.7 x 10 <sup>6</sup> cells	>80	Twice 12(100%)	IV
Häberle et al.	NR	NR	1 x 10 <sup>6</sup> cells/kg	>90	Twice 3 (60%) Three times 2 (40%)	IV
Sánchez-	AT	NR	1 x 10 <sup>6</sup>	NR	Once 2 (15.4%)	IV

Guijo et al.			cells/kg		Twice 10 (76.9%) Three times 1 (7.7%) Once 11 (35.5%)	
Guo et al.	UC	NR	$1 \times 10^6$ cells/kg	NR	Twice 9 (29.0%) Three times 11 (35.5%) Three times 15 (93.8%)	IV
Feng et al.	UC	NR	$1 \times 10^8$ cells	NR	Four times 1 (6.2%) Once 7 (28.0%)	IV
Chen et al.	NR	NR	$1 \times 10^6$ cells/kg	NR	Twice 7 (28.0%) Three times 11 (44.0%)	IV
Hashemian et al.	UC or PL	Negative: CD31, CD45, CD34, CD11b, HLD-R; Positive: CD29, CD105, CD90, CD73	$200 \times 10^6$ cells	92.7(88.7~94.2)	Twice 1 (9.1%) Three times 10 (90.9%)	IV
Iglesias et al.	UC	Negative: CD45, CD34, HLA-DR; Positive: CD44, CD105, CD90, CD73	$1 \times 10^6$ cells/kg	99.95	Once 5(100%)	IV
Yilmaz et al.	WJ	NR	NR	NR	Four times 1(100%)	The first three times: IV; The fourth time: IV + intrathecal
Zengin et al.	UC	NR	$1 \times 10^6$ cells/kg	NR	Twice 1(100%)	Intratracheal + IV
Tang et al.	MB	Negative: CD34, CD45, CD133, HLA-DR; Positive: CD29, CD73, CD90, CD105, CD9, CD44, HLA-ABC	$1 \times 10^6$ cells/kg	90 ~ 95	Three times 2(100%)	IV
Zhang et al.	WJ	Negative: CD45, CD34;	$1 \times 10^6$ cells/kg	> 90	Once 1(100%)	IV



			Positive: CD73, CD105, CD90,			
Peng et al.	UC	NR	1 x 10 <sup>6</sup> cells/kg	95.78	Three times 1(100%)	IV
Soler et al.	NR	NR	1 x 10 <sup>6</sup> cells/kg	NR	Once 1(100%)	IV
Zhu et al.	UC	NR	1 x 10 <sup>6</sup> cells/kg	NR	Once 1(100%)	IV
			Negative: CD19, CD34, CD11b, CD45, HLA-DR; Positive: CD73, CD105, CD90, CD44			
Liang et al.	UC		5 x 10 <sup>7</sup> cells	>90	Three times 1(100%)	IV
Tao et al.	WJ	NR	1.5 x 10 <sup>6</sup> cells/kg	NR	Five times 1(100%)	IV

614 Abbreviations: AT: adipose tissue, IV: intravenous, MB: menstrual blood, MSC: mesenchymal stem cell, NR: not

615 reported, PL: placenta, UC: umbilical cord, WJ: Wharton's jelly

616

**Table 4** Adverse events and mortality

Authors	Number of patients with AEs, n(%) MSC; Ctrl	Number of AEs, n MSC; Ctrl	Number of SAEs, n MSC; Ctrl	Number of AEs treatment-related, n MSC; Ctrl	Mortality, n(%) MSC; Ctrl
Leng et al.	0; 2(33.3%)	0; 2	0; 2	No; NR	0; 1(33.3%)
Meng et al.	4(44.44%); 9(100%)	5; 9	0	3; NR	0; 0
Shu et al.	NR	NR	0; 3	NR	0; 3(10.3%)
Xu et al.	20(76.92%); 18(100%)	56; 59	10; 15	NR	2(7.7%); 6(33.3%)
Shi et al.	37(56.92%); 21(60.00%)	37; 21	1; 0	NR	0; 0
Lanzoni et al.	8(66.7%); 11(91.7%)	35; 53	4; 19	Possible 1; 1	2(16.7%); 7(58.3%)
Häberle et al.	NR	NR	1; 10	NR	1(20%); 10(55.6%)
Sánchez-Guijo et al.	2(15.38%); -	2; -	2; -	0; -	2(15.4%); -
Guo et al.	NR; -	NR; -	4; -	0; -	4(12.9%); -
Feng et al.	Hypoalbuminemia, insomnia, gastrointestinal diseases, and paroxysmal arrhythmia have occurred in the surviving patients	NR; -	2; -	0; -	2(12.5%); -
Chen et al.	3; -	3; -	NR; -	3; -	0; -
Hashemian et al.	7; -	7; -	5; -	2; -	5(45.5%); -
Iglesias et al.	5; -	17; -	2; -	6; -	2(40%); -
Yilmaz et al.	1; -	1; -	1; -	0; -	0; -
Zengin et al.	0; -	0; -	0; -	0; -	0; -
Tang et al.	NR; -	NR; -	NR; -	NR; -	0; -
Zhang et al.	0; -	0; -	0; -	0; -	0; -
Peng et al.	0; -	0; -	0; -	0; -	0; -
Soler et al.	0; -	0; -	0; -	0; -	0; -
Zhu et al.	0; -	0; -	0; -	0; -	0; -
Liang et al.	0; -	0; -	0; -	0; -	0; -
Tao et al.	NR; -	NR; -	NR; -	0; -	1; -

617 Abbreviations: AE: adverse events, **Ctrl**: control group, **MSC**: mesenchymal stem cell treatment group, NR: not reported,

618 SAE: serious adverse event

**Table 5** Clinical symptoms and imaging outcomes

Authors	The time from intervention to recovery	General clinical symptoms	Imaging outcomes
Leng et al.	NR	<b>MSC: Day 4</b> , the respiratory rate was decreased to the normal range, fever and shortness of breath disappeared, and SaO <sub>2</sub> rose from 89% to 98% <b>Ctrl: NR</b>	<b>MSC: Day 9</b> , the GGO and pneumonia infiltration were largely reduced <b>Ctrl: NR</b>
Meng et al.	The interval between admission and discharge: <b>MSC</b> vs. <b>Ctrl</b> : 20.00(17.50, 24.50) days vs. 23.00(20.00, 27.00) days	<b>MSC: In most severe patients</b> , the PaO <sub>2</sub> /FiO <sub>2</sub> ratio improved	<b>MSC: CT scans</b> indicated that patients showed absorption of pulmonary pathological changes. The severe patient 9 showed that the lung lesions were well controlled within 6 days, and completely faded away within 2 weeks <b>Ctrl: The lung lesions</b> of the severe patient 7 still existed at discharge
Shu et al.	The time to clinical improvement in <b>MSC</b> group was shorter than that in <b>Ctrl</b> group: 9.0 (6.0, 13.0) days vs. 14.0 (9.5, 21.0) days, P<0.01	The oxygenation index of <b>MSC</b> group recovered to the normal range faster than <b>Ctrl</b> group <b>MSC vs. Ctrl</b> Clinical improvement, n (%): <b>Day 3</b> : 2(16.67%) vs. 1(3.45%). <b>Day 7</b> : 7(58.33%) vs. 5(17.24%), P<0.05. <b>Day 14</b> : 11(91.67%) vs. 15(51.72%), P<0.05. <b>Day 28</b> : 12(100%) vs. 25(86.21%)   Hospital stay: median (IQR): 20.00(16.00, 24.00) days; 24.00 (20.00, 26.50) days <b>Seven-category scale</b> (scale 1~7): <b>Day 7</b> : 0/1/7/3/1/0/0 vs. 0/0/3/19/5/2/0. <b>Day 14</b> : 0/5/6/1/0/0/0 vs. 0/5/17/1/2/1/3	<b>Two weeks: Chest CT</b> indicated that CT scores, the number of lobes involved, GGO, and consolidation, which reflected reduced lung inflammation in <b>MSC</b> group, were significantly better than those in <b>Ctrl</b> group <b>MSC vs. Ctrl</b> <b>CT score</b> : 8.50 (7.25, 9.00) vs. 10.00 (8.50, 12.50); P<0.05   <b>Number of lobes involved</b> : 2 (2, 2) vs. 3 (2, 3); P< 0.01   <b>GGO</b> : 4 (33.33%) vs. 19 (70.37%); P<0.05   <b>Consolidation</b> : 4 (33.33%) vs. 20 (74.07%); P<0.05
Xu et al.	The average time to improvement: <b>MSC</b> vs. <b>Ctrl</b> : (3.00 ± 3.05) d vs. (8.80 ± 10.77) d, P<0.05 There was no significant difference in either the length of hospital stay or in the number of days in the ICU between the two groups	<b>MSC: There were no significant differences</b> in FiO <sub>2</sub> and SaO <sub>2</sub> before and after MSCs infusion, but SpO <sub>2</sub> (from 94.72 ± 3.4% to 96.04 ± 5.93%) and PaO <sub>2</sub> (from 78.89 ± 25.86 mmHg to 95.62 ± 39.49 mmHg) were significantly improved	<b>One month: The relative improvement rate</b> was higher for <b>MSC</b> group than it was for <b>Ctrl</b> group. <b>MSC vs. Ctrl</b> : 85.0% (17/20) vs. 50% (6/12)
Häberle et al.	NR	At discharge, the <b>MSC-treated patients</b> showed a significantly lower Murray score of 0.3 + 0.1 than the <b>Ctrl patients</b> , who presented an average score of 1.3 + 1.1	NR
Lanzoni et al.	Time to recovery was significantly shorter in <b>MSC</b> group than in <b>Ctrl</b> group (P<0.05). The hazard ratio for recovery comparing <b>Ctrl</b> group with <b>MSC</b> group was 0.29	NR	NR

(95% CI: 0.09-0.95)

Shi et al.	NR	<p><b>MSC: Day 1</b>, the cough showed a significant improvement compared to the <b>Ctrl</b> group, but no difference was found at other time points. <b>Day 1, 3, and 5</b>, the expiratory dyspnea showed a significant improvement compared to the <b>Ctrl</b> group, but no difference was found at <b>Day 7, 14, and 30</b></p> <p><b>MSC vs. Ctrl</b></p> <p><b>Six-category scale</b> (scale 1~6): <b>Day 10</b>, 11/8/44/2/0/0; 6/6/23/0/0/0   <b>6-MWT: Day 28</b>, median (IQR): 420.00 (392.00, 465.00) m vs. 403.00 (352.00, 447.00) m   <b>mMRC dyspnea score</b> (grade 0~4): 29/24/5/3/0 vs. 13/16/4/1/1   <b>SaO<sub>2</sub></b>: 97.10% vs. 96.97%</p>	<p><b>MSC vs. Ctrl</b></p> <p><b>Day 28:</b> The change of total lesion proportion of the whole lung volume (median, 95% CI, %): -19.40 (-53.40, -2.62) vs. -7.30 (-46.59, 19.12)   The change of solid component lesions (median, 95% CI, %): -57.70 (-74.95, -36.56) vs. -44.45 (-62.24, -8.82); P&lt;0.05   The change of GGO (%): -14.95 (-51.55, 7.29) -3.94 (-43.99, 32.55)</p>
Sánchez-Guijo et al.	NR	<p><b>MSC:</b> After a median follow-up of 16 days (IQR 9 days) after the first dose of MSCs, 9 (70%) patients had improved clinically and 7 (53%) were extubated with a median time from the first MSCs dose to extubation of 7 days (IQR 14 days)</p>	<p><b>MSC:</b> Radiological improvement in sequential X-rays was confirmed in 4 patients</p>
Guo et al.	NR	<p><b>MSC:</b> PaO<sub>2</sub>/FiO<sub>2</sub>: Increased from 242 (200–294) mmHg to 332 (288–364) mmHg, P &lt; 0.01</p> <p><b>MSC:</b> The oxygenation index increased into 329.00 (197.70-604.00) mmHg and 316.84 (93.30-531.00) mmHg in severe patients (n = 9) and critically severe patients (n = 6) with the oxygenation index in total 325.70 (93.30-604.00) mmHg on <b>Day 7</b></p> <p>The oxygenation index was 356.95 (107.50-452.40) mmHg and 453.79 (306.00-552.30) mmHg in severe patients (n = 4) and critically severe patients (n = 4) with the oxygenation index in total 394.79 (107.50-552.30) mmHg on <b>Day 14</b></p>	NR
Feng et al.	NR	<p><b>MSC:</b> All cases gained clinical improvement</p> <p><b>MSC:</b> The results of the survivors showed that the median time to relief after the first infusion was 2.5 days for fever, 3 days for respiratory rate (<math>\leq 24/\text{min}</math>), and 2 days for cough (mild or absent). Most patients described significant relief of their</p>	<p><b>MSC:</b> The radiological presentations (GGO) all showed improvement compared with baseline</p>
Chen et al.	NR	<p><b>MSC:</b> Five patients significantly improved and were discharged from the ICU, 2 to 7 days after the infusions</p>	<p><b>MSC:</b> After MSCs therapy, 16 cases (64%) gained CT scan improvement</p> <p><b>MSC:</b> The lung CT was available after therapy in three survived cases. The lung CT scans of two patients showed significant resolution of opacities and the subpleural bands after completion of MSCs therapy</p>

Iglesias et al.	<p><b>MSC:</b> Patient 1: Discharged from the ICU on <b>Day 10</b> and discharged from the hospital 2 weeks later. Patient 2: Discharged from the ICU on <b>Day 12</b> and discharged from the hospital 4 days later. Patient 3: Discharged <b>from</b> the hospital on <b>Day 21</b>. Patients 4 and 5 died</p>	<p>dyspnea and there was a decrease in respiratory rate within 48–96 h after the first cell infusion. The saturation of pulse oxygen significantly improved in survivors (9.2 [3.7 – 14.6]%) compared to non-survivors (6.6 [5.01–11.0]%)</p>	<p><b>MSC:</b> Chest CT showed that the proportion of damaged lung parenchyma in the three surviving patients was significantly reduced following MSCs treatment, while that in the two patients who died did not decrease but increased</p>
Yilmaz et al.	NR	<p><b>MSC:</b> After the first 2 times MSCs injection, the patient was awakened and extubated. The patient's vital signs were improved, especially after intrathecal and systemic MSCs transplantation. After the patient had been extubated, his neurological symptoms regressed, consciousness restored, and he could speak. After system transplantation of MSCs, the ejection fraction increased from 25% during cardiac arrest to 60%. After four times MSCs transplantation, the patient's heart functions have returned to normal</p>	<p><b>MSC:</b> After the last time MSCs transplantation, bilateral lung symptoms regressed on control thorax CT</p>
Tang et al.	NR	<p><b>MSC: Case 1: Day 5:</b> The symptoms of fever and dyspnea improved. SaO<sub>2</sub>: 97%, PaO<sub>2</sub>: 86 mmHg, FiO<sub>2</sub>: 55%  <b>Case 2: Day 7:</b> SaO<sub>2</sub>: 99%, PaO<sub>2</sub>: 169 mmHg, and FiO<sub>2</sub>: 30%</p>	<p><b>MSC: Case 1:</b> The X-ray on <b>Day 1</b> and <b>Day 5</b> showed the absorption of the exudate lesions in the bilateral lungs  <b>Case 2:</b> The chest X-ray showed the absorption of high-density exudate in the lower lung fields and left middle lung</p>
Zhang et al.	<p><b>MSC:</b> After 1 week of MSCs treatment, the patient felt better and was discharged after another day</p>	<p><b>MSC: Day 2,</b> fever and shortness of breath disappeared. All the symptoms disappeared, and the SaO<sub>2</sub> rose to 98% at rest after transplantation 2~7 days</p>	<p><b>MSC: Day 6,</b> chest CT imaging showed that the GGO and pneumonia infiltration had largely reduced</p>
Zengin et al.	NR	<p><b>MSC:</b> Following MSCs transplantation, the need for inotropic agents started to disappear, hypoxemia, acidosis and electrolyte imbalance started to improve.  <b>Day 10,</b> the patient was extubated and continued to be monitored in the ward, initially receiving nasal oxygen which was later discontinued. Two months, the patient had normal</p>	<p><b>MSC: Day 7,</b> lung chest X-ray showed slight regression in the GGO imaged infiltration in the middle right lung periphery and significant regression in the low-density infiltrations in the lower right lung and lateral left lung</p>

Peng et al.	<b>MSC: Day 11</b> , the patient recovered and discharged	clinical and laboratory signs and no adverse effects due to the procedure were identified <b>MSC: Day 11</b> , the symptoms of dyspnea and dry cough improved significantly, and the endurance of daily activities improved. Oxygenation index and PaO <sub>2</sub> gradually increased	<b>MSC: Day 5</b> , the chest CT showed the bilateral infiltration was absorbed obviously
Soler et al.	<b>MSC: Day 6</b> , the patient was discharged from the hospital	<b>MSC: Day 4</b> , the lung function test was completely normal. <b>Day 5</b> , the clinical symptoms related to the coronavirus had disappeared, but the loss of appetite and fatigue were maintained <b>MSC: Day 2</b> , SpO <sub>2</sub> recovered from 87% to 95%. <b>Day 6</b> , the cough symptoms of the patient were relieved, and there was no sputum when coughing, and the ventilator was removed	<b>MSC: Day 5</b> , CT showed significant improvement in the right pneumonia
Zhu et al.	<b>MSC: Day 13</b> , the patient was discharged from the hospital	<b>MSC: Day 8</b> , the patient was transferred out of ICU, and most of the vital signs and clinical laboratory indexes recovered to the normal level <b>MSC: Day 2</b> , the consciousness and mental status began to get better. Pulmonary static compliance increased significantly, and PaO <sub>2</sub> /FiO <sub>2</sub> mostly maintained above 200 mmHg. ECMO and mechanical ventilation couldn't be removed due to no significant improvement in lung function	<b>MSC: Day 7</b> , CT showed that the GGO and pneumonia infiltration had reduced obviously
Liang et al.	<b>MSC: Day 18</b> , the patient was discharged from the hospital		<b>MSC: Day 7</b> , CT showed that the GGO and pneumonia infiltration had reduced obviously
Tao et al.	<b>MSC: Day 11</b> , the patient received lung transplantation. But died 77 days after lung transplantation because of transplant rejection		<b>MSC: Day 7</b> , CT showed that the GGO and pneumonia infiltration had reduced obviously

620 Abbreviations: **Ctrl**: Control group, ECMO: extracorporeal membrane oxygenation, GGO: ground-glass opacity, IQR:  
621 interquartile range, ICU: intensive care unit, **MSC**: mesenchymal stem cell treatment group, MSCs: mesenchymal stem  
622 cells, NR: not reported, PaO<sub>2</sub>/FiO<sub>2</sub>: arterial blood partial pressure of oxygen (PaO<sub>2</sub>)/fraction of inspiration O<sub>2</sub> (FiO<sub>2</sub>),  
623 SaO<sub>2</sub>: oxygen saturation, SpO<sub>2</sub>: peripheral oxygen saturation, 6-MWT: the 6-minute walk test  
624 **Note: Day**: Time starts from the first injection of MSCs

**Table 6** Laboratory outcome

Authors	HCoV-19 nucleic acid detection	Immune cells	Inflammatory cytokines
Leng et al.	<p><b>MSC:</b> The critically severe patient 1: 13 days after transplantation, nucleic acid turned to be negative. Patients 3, 4, and 5 also turned to be negative for nucleic acid until this report date</p> <p><b>Ctrl:</b> NR</p>	<p><b>MSC:</b> Two common type patients (Patient 4 and 5): there was nearly no increase of regulatory <b>T cells (CXCR3-)</b> or <b>DC (CXCR3-)</b>. The severe patients: both the regulatory <b>T cells</b> and <b>DC</b> increased after the cell therapy. The critically severe patient 1: <b>Day 6</b>, the overactivated <b>T cells</b> and <b>NK cells</b> nearly disappeared and the numbers of the other cell subpopulations were almost restored to the normal levels, especially the regulatory <b>DC (CD14+CD11c+CD11b<sup>mid</sup>)</b> population</p> <p><b>Ctrl:</b> No significant <b>DC (CXCR3-)</b> enhancement was observed</p>	<p><b>MSC:</b> The critically severe patient 1: <b>CRP</b> level decreased from 105.5 g/L to 10.1g/L; <b>AST</b>, <b>CK</b> activity and <b>myoglobin</b> were decreased to normal reference values in 2~4 days after treatment.</p> <p>Compared with Ctrl group, the decrease ratio of <b>TNF-α</b> and the increase ratio of <b>IL-10</b> before and after MSC treatment of MSC group were significant (p&lt;0.05). The serum levels of <b>IP-10</b> and <b>VEGF</b> were both increased, though not significantly</p> <p>The laboratory parameters improved in both groups</p> <p><b>MSC:</b> two moderate type patients and two severe type patients with high baseline <b>IL-6</b> exhibited a decline of <b>IL-6</b> within 3 days after MSCs infusion and remained stable during the following 4 days. No such trend in the patients with lower plasma <b>IL-6</b> levels, which suggested that the patients with high <b>IL-6</b> might be more likely to benefit from MSCs treatment</p> <p>There was a reduced trend in the levels of inflammatory cytokines (including <b>IFN-γ</b>, <b>TNF-α</b>, <b>MCP-1</b>, <b>IP-10</b>, <b>IL-22</b>, <b>IL-1Ra</b>, <b>IL-18</b>, <b>IL-8</b>, and <b>MIP-1</b>) within 14 days</p> <p><b>Ctrl:</b> NR</p>
Meng et al.	<p>The anti-SARSCoV-2 IgM antibody tests were positive for all patients. The median IgG and IgM antibodies titer numerically but not statistically decreased between the two group</p>	NR	<p><b>Day 3:</b> Compared with Ctrl group, <b>CRP</b> and <b>IL-6</b> levels were significantly decreased from of stem cell infusion in <b>MSC</b> group</p> <p><b>MSC:</b> There were no significant differences in <b>CRP</b> and <b>IL-6</b> before and after MSC infusion</p> <p><b>Ctrl:</b> NR</p>
Shu et al.	NR	<p>Compared with Ctrl group, the time for the <b>LYM</b> count of <b>MSC</b> group to return to the normal range was significantly faster</p>	<p><b>Day 3:</b> Compared with Ctrl group, <b>CRP</b> and <b>IL-6</b> levels were significantly decreased from of stem cell infusion in <b>MSC</b> group</p>
Xu et al.	<p>The nucleic acid turns into negative time:<b>MSC</b> (15.75 ± 13.71) days; <b>Ctrl</b> (18.31 ± 9.86) days</p>	NR	<p><b>MSC:</b> There were no significant differences in <b>CRP</b> and <b>IL-6</b> before and after MSC infusion</p> <p><b>Ctrl:</b> NR</p>
Shi et al.	NR	<p>There was no significant difference in the subsets of peripheral <b>LYM</b> counts (<b>CD4+ T cells</b>, <b>CD8+ T cells</b>, <b>B cells</b>, <b>NK cells</b>) between <b>Ctrl</b> group and <b>MSC</b> group at <b>Day 0</b>, <b>6</b>, <b>10</b>, and <b>14</b></p>	<p>There was no significant difference in plasma markers (<b>IL-6</b>, <b>IL-8</b>, <b>IFN-γ</b>, <b>IL-1Ra</b>, <b>IL-18</b>, <b>MCP-1</b>, <b>MIP-1α</b>, and <b>IP-10</b>) between <b>Ctrl</b> group and <b>MSC</b> group at <b>Day 0</b>, <b>6</b>, <b>10</b>, and <b>14</b></p>
Häberle et al.	NR	<p><b>MSC:</b> Compared with <b>Ctrl</b> group, significant reduction in <b>WBCs</b> and <b>NE</b>, and significant increase in <b>LYM</b> were be found</p>	<p><b>MSC:</b> Compared with <b>Ctrl</b> group, <b>CRP</b> and <b>IL-6</b> were not significant difference; but <b>ferritin</b> levels showed a significant increase</p>
Lanzoni et	The median viral	NR	<p><b>Day 6</b>, the concentrations of <b>GM-CSF</b>,</p>



al.	load at <b>Day 0</b> or <b>Day 6</b> did not differ significantly between <b>MSC</b> group and <b>Ctrl</b> group		<b>IFN-g, IL-5, IL-6, IL-7, TNF-<math>\alpha</math>, TNF-<math>\beta</math>, PDGF-BB</b> and <b>RANTES</b> in <b>MSC</b> group were significantly lower than those in <b>Ctrl</b> group ( $P < 0.05$ ). The difference of <b>IL-2</b> is very close to statistical significance ( $P = 0.051$ ). In longitudinal analysis, only in <b>MSC</b> group, the inflammatory cytokine concentration showed a statistically significant decrease from <b>Day 0</b> to <b>Day 6</b>
Sánchez-Guijo et al.	NR	<b>MSC:</b> <b>LYM</b> subset analysis was available in six improved patients at <b>Day 10</b> , and the levels of <b>total LYMs</b> (5/6), <b>B</b> (4/6) and <b>CD4+</b> (5/6) and <b>CD8+</b> (5/6) and <b>T</b> (6/6) <b>cells</b> were observed an increase	<b>MSC:</b> <b>Day 5</b> , a decrease in inflammatory parameters associated with MSC therapy was observed in the nine improved clinically patients (n): <b>D-dimer:</b> 5/8; <b>Ferritin:</b> 5/8; <b>CRP:</b> 8/9; <b>Fibrinogen:</b> 5/9; <b>LDH:</b> 9/9 <b>MSC:</b> Comparison before and after MSC treatment: <b>CRP</b> (mg/L): 13.39 (1.30–38.86) vs. 0.50 (0.50–6.40) $P < 0.01$   <b>PCT</b> (ng/ml): 0.07 (0.05–0.09) vs. 0.04 (0.03–0.06) $P < 0.01$   <b>IL-6</b> (pg/ml): 13.78 (5.69–25.26) vs. 4.86 (2.13 – 8.19) $P < .001$   <b>D-dimer</b> (ng/ml): 495 (320–727) vs. 288 (197–537) $P < 0.01$
Guo et al.	<b>MSC:</b> After the first infusion of MSCs, the SARS-CoV-2 PCR results of 30 patients (96.8%) became negative after a mean time of 10.7 $\pm$ 4.2 days	<b>MSC:</b> Comparison before and after MSC treatment: <b>WBC</b> ( $\times 10^9$ /ml): 6.72 $\pm$ 2.62 vs. 6.43 $\pm$ 1.72, $P = 0.3461$ ; <b>LYM</b> ( $\times 10^9$ /ml): 1.09 (0.68–1.35) vs. 1.43 (1.02–2.20) $P < 0.01$	
Feng et al.	NR	<b>MSC:</b> The <b>WBC</b> count was similar in each follow-up, whereas the <b>LYM</b> count showed recovery after MSCs transplantation Only got 5 (5/16) patients' results enrolled at <b>Day 28</b> : The <b>CD4+ T cells</b> , <b>CD8+ T cells</b> and <b>NK cells</b> , showed recovery after MSCs transplantation	<b>MSC:</b> The cytokines, including <b>IL-2, IL-4, IL-6, IL-10, TNF-<math>\alpha</math>, IFN-<math>\gamma</math></b> and <b>CRP</b> , varied in the normal range after MSCs transplantation. <b>PCT</b> level was relatively low in the enrolled patients
Chen et al.	NR	NR	<b>MSC:</b> Inflammation indexes, including <b>WBC</b> counts, <b>CRP</b> , <b>PCT</b> and <b>IL-6</b> did not change significantly after MSCs therapy. However, the serum levels of <b>LAC</b> , <b>cTnT</b> and <b>CK-MB</b> elevated significantly <b>MSC:</b> Analysis of biomarkers on <b>Day 0</b> (baseline) and <b>Day 5</b> after the first infusion (24 h after the last infusion) showed a significant reduction in <b>IL-8, TNF-<math>\alpha</math></b> , and <b>CRP</b> ) in all <b>six survivors</b> . Serum <b>IL-6</b> levels decreased in five (5/6) patients and <b>INF-<math>\gamma</math></b> levels decreased in four (4/6) patients. Anti-inflammatory cytokines including <b>IL-4</b> and <b>IL-10</b> levels increased in four (4/6) patients, but the differences were not statistically significant
Hashemian et al.	NR	NR	
Iglesias et al.	NR	<b>MSC:</b> Total <b>LYMs</b> were minimally elevated 7 days post-infusion. Only	<b>MSC:</b> All patients developed increased <b>D-dimer</b> concentrations after



		patient 1 had a decrease in total <b>LYMs</b> from 1570/ml to 984/ml	the first 24 hours post-infusion of between 2738 ng/ml and 4712 ng/ml. After this time, D-dimer concentrations decreased; however, there were value fluctuations due to patients' added complications. <b>CRP</b> concentrations remained normal in patients 1, 2, and 3 during the first 7 days. In the patients who died (Patients 4 and 5), <b>CRP</b> concentrations increased during the same period
Yilmaz et al.	NR	<b>MSC:</b> The number of <b>TH-2 cells</b> increased, and the number of <b>TH-1 cells</b> decreased in the immune modulation after MSC transplantation. After the first MSC transplant, the proportions of <b>CD4+T cells</b> and <b>CD8+T cells</b> were 66 % and 26.7 %, respectively. After the second and third MSC transplantations, the proportion of <b>CD4+T cells</b> was 42.9 % and 39.1 %, while that of <b>CD8+T cells</b> was 18.7 % and 22 %, respectively	<b>MSC:</b> After the first MSC transplantation, the values of <b>AST, ALT, LDH, CK, pro-BNP, ferritin, triglyceride, fibrinogen, ammonia,</b> and <b>myoglobin</b> began to decrease. The second time the MSCs had been given, <b>CRP</b> reached normal values
Zengin et al.	NR	NR	<b>MSC:</b> The <b>CRP</b> levels regressed
Tang et al.	MSC: Case 1: The patient's nucleic acid test turned negative Case 2: The patient's nucleic acid test turned negative on Day 8	<b>MSC: Case 1:</b> The <b>LYM</b> increased. <b>Case 2:</b> The <b>LYM</b> increased.	<b>MSC: Case 1:</b> The inflammation indicators ( <b>CRP, IL-6</b> ) decreased <b>Case 2:</b> The inflammation indicators ( <b>CRP</b> ) decreased
Zhang et al.	<b>MSC: Day 6,</b> nucleic acid turned to be negative	<b>MSC:</b> The immunoregulatory function of MSCs contributed to the main efficacy outcome. The percentage and counts of <b>CD3+ T cell, CD4+ T cell,</b> and <b>CD8+ T cell</b> were increased	<b>MSC:</b> The <b>CRP</b> levels and inflammatory factors ( <b>IL-6</b> and <b>TNF-<math>\alpha</math></b> ) were all decreased after MSC treatment
Peng et al.	<b>MSC: Day 4,</b> the nucleic acid test was negative	<b>MSC:</b> The absolute <b>NE count</b> continued to decrease; the absolute <b>LYM count</b> gradually increased <b>MSC:</b> One week, the absolute number of <b>LYMs</b> of the patient was significantly increased ( <b>Total LYMs:</b> from 201/ml to 651/ml; <b>T cells:</b> from 152/ml to 547/ml; <b>B cells:</b> from 21.8/ml to 46.8/ml; <b>NK cells</b> from 17.9/ml to 29.3/ml). <b>Day 13,</b> the number of <b>LYM</b> and <b>NE</b> returned to normal	<b>MSC: IL-6</b> continued to decrease
Zhu et al.	<b>MSC: Day 13,</b> the nucleic acid was negative		<b>MSC:</b> Time to return to normal range: <b>Day 5: BUN; Day 10: AST, ALT; Day 13: CRP, PCT</b>
Soler et al.	<b>MSC: Day 4,</b> the nucleic acid was negative	NR	<b>MSC: Day 5,</b> all biochemical indicators were within the normal range
Liang et al.	<b>MSC: Day 8,</b> the nucleic acid was negative	<b>MSC:</b> After the second administration, the <b>WBC</b> count and <b>NE</b> count decreased to the normal level, along with the <b>LYM</b> count increased to the normal level as well. The counts of <b>CD3+ T cell, CD4+ T cell,</b> and <b>CD8+</b>	<b>MSC:</b> After the second administration, the concentrations of serum <b>bilirubin, CRP, ALT</b> and <b>AST</b> gradually reduced, along with some other vital signs also improved. The <b>D-dimer</b> levels also decreased gradually

**T cell** also remarkably increased to normal levels. The **NE-to-LYM** ratio also decreased gradually

Tao et al. **MSC:** The number of **LYM** began to increase. However, the number of **WBC** and **NEs** remained high **MSC: Blood creatinine** and **BUN** declined remarkably, suggesting renal function began to improve

626 Abbreviations: ALT: alanine aminotransferase, AST: aspartate transaminase, BNP: B-type natriuretic peptide, BUN:  
627 blood urea nitrogen; CK: creatine kinase, CK-MB: creatine kinase-MB, CRP: C-reactive protein, cTnT: cardiac troponin  
628 T, **Ctrl**: Control group, DC: dendritic cells, GM-CSF: granulocyte-macrophage colony-stimulating factor, INF- $\gamma$  or IFN-  
629  $\gamma$ : interferon- $\gamma$ , IFN-g: interferon-g, IL-1RA: interleukin-1RA, IL-2: interleukin-2, IL-4: interleukin-4, IL-5: interleukin-5,  
630 IL-6: interleukin-6, IL-7: interleukin-7, IL-8: interleukin-8, IL-10: interleukin-10, IL-18: interleukin-18, IL-22:  
631 interleukin-22, IP-10: interferon-inducible protein-10, LAC: lactate; LDH: lactate dehydrogenase, LYM: lymphocyte,  
632 MCP-1: monocyte chemotactic protein-1, MIP-1 $\alpha$ : macrophage inflammatory protein-1 $\alpha$ , **MSC**: mesenchymal stem cell  
633 treatment group, MSC: mesenchymal stem cell, NE: Neutrophil, NK: natural killer, NR: not reported, PCT: procalcitonin,  
634 PDGF-BB: platelet derived growth factor-BB, RANTES: regulated upon activation normal T cell expressed and secreted  
635 factor, TNF- $\alpha$ : tumor necrosis factor- $\alpha$ , TNF- $\beta$ : tumor necrosis factor- $\beta$ , VEGF: vascular endothelial growth factor,  
636 WBC: white blood cell  
637 **Note: Day**: Time starts from the first injection of MSCs

638

## Figure Legends

639 **Figure 1** Flow chart

640 **Figure 2** Pooled estimate for the number of adverse events

641 **Figure 3** Pooled estimate for mortality. **A** Forest plots of mortality. **B** Funnel plot of mortality

**Identification**

Records identified through  
database searching  
(n = 1582)

**Screening**

Records after duplicates  
removed  
(n = 1582)

Records screened  
(n = 1582)

Records excluded by title and  
abstract  
(n = 1413)

**Eligibility**


Full-text articles assessed  
for eligibility  
(n = 169)

Full-text articles excluded  
with reasons (n = 147):  
Studies on the treatment of  
MSC-derived exosomes or  
extracellular vesicles (n = 29)  
Reviews, Letters (without  
data), editorials, commentary,  
opinion (n = 112)  
Repetition (n = 3)  
Study on follow-up data after  
discharge (n = 1)  
No full-text available (n = 1)  
Study with incomplete data  
(n = 1)

Studies included in  
qualitative synthesis  
(n = 22)

**Included**

Studies included in  
quantitative synthesis  
(meta-analysis)  
(n = 22)




A

Study or Subgroup	MSC group		Ctrl group		Weight	Odds Ratio	
	Events	Total	Events	Total		M-H, Fixed, 95% CI	
Häberle 2021	1	5	10	18	17.6%	0.20	[0.02, 2.16]
Lanzoni 2021	2	12	7	12	29.5%	0.14	[0.02, 0.96]
Leng 2020	0	7	1	3	9.5%	0.11	[0.00, 3.70]
Meng 2020	0	9	0	9		Not estimable	
Shi 2021	0	65	0	35		Not estimable	
Shu 2020	0	12	3	29	10.3%	0.30	[0.01, 6.32]
Xu 2021	2	26	6	18	33.1%	0.17	[0.03, 0.95]
<b>Total (95% CI)</b>		<b>136</b>		<b>124</b>	<b>100.0%</b>	<b>0.17</b>	<b>[0.06, 0.49]</b>

Total events

5

27

Heterogeneity:  $\text{Chi}^2 = 0.25$ ,  $\text{df} = 4$  ( $P = 0.99$ );  $I^2 = 0\%$ Test for overall effect:  $Z = 3.33$  ( $P = 0.0009$ )

**B**